echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lingke Pharmaceutical's LNK01001 clinical phase II study completed the first patient dosing

    Lingke Pharmaceutical's LNK01001 clinical phase II study completed the first patient dosing

    • Last Update: 2022-05-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 28, Lingke Pharmaceutical announced that its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases has completed the first patient dosing in its Phase II clinical trial for Atopic Dermatitis (AD)


    Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that often occurs on the face, neck, and elbow fossa


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.